• The system runs unattended for up to 60 hours, facilitating more than 20,000 injections and enabling over-the-weekend runs. • It analyzes multiple assays in a single, unattended run. • It automates method development for novel analytes. • It provides intuitive data review and visualization, using RapidFire Integrator 2.0 software.

The RapidFire 365 can also identify active compounds against challenging targets, confirm the activity of those compounds, and assess absorption, distribution, metabolism, elimination and physiochemical properties of those compounds.

"Agilent is excited to offer a single end-to-end platform for fast, cost-effective, automated, walkaway mass spectrometric analysis," said Can (Jon) Ozbal, Ph.D., director of RapidFire operations. "The RapidFire 365 brings us closer to our vision of creating a label-free MS-based workflow that rivals the simplicity of a plate reader while avoiding the pitfalls of optical assays."

The new RapidFire system offers a strong application focus in HTS, including epigenetics and fragment-based drug discovery, as well as generating equivalent data to HPLC-MS in a fraction of the time and cost for a wide range of clinical research and forensic toxicology applications.

Agilent's RapidFire solutions-front-end systems based on solid-phase extraction-enable detection of native compounds by mass spectrometry. Requiring no labels or surrogates, RapidFire technology allows users to screen intractable or challenging targets that are not amenable to fluorescence or luminescence. Sample throughput is 10 times faster than conventional MS screening methods.